


## Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel—Letter

María Apellániz-Ruiz<sup>1</sup>, Lara Sánchez-Barroso<sup>1</sup>, Gerardo Gutiérrez-Gutiérrez<sup>2</sup>, María Sereno<sup>3</sup>, Jesús García-Donás<sup>4</sup>, Elisabeth Åvall-Lundqvist<sup>5</sup>, Henrik Gréen<sup>6,7,8</sup>, Kim Brøsen<sup>9</sup>, Troels K. Bergmann<sup>9</sup>, and Cristina Rodríguez-Antona<sup>1,10</sup>

We have with great interest read the pharmacogenetic study by Abraham and colleagues (1) reporting SNPs associated with paclitaxel-induced neuropathy. The identification of markers predictive of sensory neuropathy is an important clinical problem for taxanes, vinca-alkaloids, platinum compounds, bortezomib, and thalidomide, among other anticancer drugs. In this respect, the study by Abraham and colleagues is a remarkably large study investigating 73 SNPs previously associated with taxane-related sensory neuropathy (TRSN) in 1,303 European individuals treated with paclitaxel (1). The authors found significant results for nine SNPs, including *EPHA6*-rs301927. Two genome-wide association studies (GWAS; refs. 2, 3) suggest *EPHA5*-rs7349683 as a neuropathy marker (meta-analysis *P* value of  $1.4 \times 10^{-9}$ ), and in our study, other members of the Eph receptor family members were also associated with paclitaxel-induced neuropathy (3).

To follow up our initial results suggesting that ephrin type A receptors are important factors influencing TRSN, we analyzed

detailed neuropathy data, recorded cycle by cycle using the NCI-CTCAE, from 146 patients treated with first-line paclitaxel. Patients had either ovarian (72%) or breast cancer; 57 (39%) were prospectively recruited in Spain and 89 patients were from a previously described Danish cohort (4). The study was approved by the corresponding ethical review committees and was carried out in accordance with the Helsinki declaration. We genotyped 4 SNPs in *EPHA4*, *EPHA5*, *EPHA6*, and *EPHA8* genes (rs17348202, rs7349683, rs301927, and rs209709, respectively) and 3 SNPs in *XKR4*, *PIK3IP1*, and *SGCG* genes (rs4737264, rs5749248, and rs1753097, respectively), all top signals in our GWAS (3). When tested against TRSN using a cumulative dose analysis, all SNPs in *EPHA* genes, except for *EPHA4*-rs17348202 (minor allele frequency = 0.05, indicating low statistical power), were associated with an increased neuropathy risk (Fig. 1). When analyzing the SNPs using maximum neuropathy grade, only *EPHA6*-rs301927 showed a trend toward increased toxicity (*P* = 0.069), suggesting



**Figure 1.**

Kaplan-Meier comparisons by *EPHA* SNPs. Paclitaxel-treated patients grouped according to *EPHA5*-rs7349683, *EPHA6*-rs301927, and *EPHA8*-rs209709 and compared with the cumulative dose of paclitaxel up to the development of grade 2 peripheral sensory neuropathy. *P* values correspond to Cox regression analysis including country as covariate; results from rs7349683 correspond to recessive genetic model.

<sup>1</sup>Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. <sup>2</sup>Neurology Section, Hospital Universitario Infanta Sofía, Madrid, Spain. <sup>3</sup>Medical Oncology Department, Hospital Universitario Infanta Sofía, Madrid, Spain. <sup>4</sup>Gynecological and Genitourinary Tumors Programme, Centro Integral Oncológico Clara Campal CIOCC, Madrid, Spain. <sup>5</sup>Department of Gynecologic Oncology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden. <sup>6</sup>Clinical Pharmacology, Division of Drug Research, Department of Medical and Health Sciences, Faculty of Health Sciences, Linköpings Universitet, Linköping, Sweden. <sup>7</sup>Science for Life Laboratory, School of Biotechnology, Division of Gene Technology, Royal Institute of Technology, Solna, Sweden. <sup>8</sup>Department of Forensic Genetics and Forensic Toxicology, National

Board of Forensic Medicine, Linköping, Sweden. <sup>9</sup>Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark. <sup>10</sup>ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.

**Corresponding Author:** Cristina Rodríguez-Antona, Spanish National Cancer Research Center (CNIO), Melchor Fernández Almagro, 3, Madrid 28029, Spain. Phone: 34-917-328-000; Fax 34-912-246-972; E-mail: crodriguez@cnio.es

**doi:** 10.1158/1078-0432.CCR-14-1885

©2015 American Association for Cancer Research.

that cumulative dose analysis is more sensitive to detect differences in neuropathy. No evidence of association was found for SNPs in other genes.

From a biologic perspective, Eph receptors represent a family of receptor kinases, involved in axon guidance and other neural-related functions, such as neuronal regeneration following nerve injury (5). Thus, this prospective study, together with that from Abraham and colleagues and previous reports, supports an increased TRSN risk for *EPHA5*-rs7349683 (2, 3), *EPHA6*-rs301927 (1, 3), and *EPHA8*-rs209709 (3). Furthermore, because EPHA proteins mediate neural injury repair, these SNPs could act as broad-spectrum neuropathy risk markers relevant for many neurotoxic drugs. Abraham and colleagues performed an exhaustive study of SNPs previously associated with TRSN; however, in view of these results, it would be interesting if the authors could further investigate these potentially clinically relevant markers

(e.g., *EPHA8*-rs209709 and *EPHA5*-rs7349683 under different genetic models).

#### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

#### Grant Support

This work was supported by projects from the Spanish Ministry of Economy and Competitiveness (grant number SAF2012-35779), the Danish Ministry of Interior Affairs and Health (2001-2007; J.nr 2006-12103-276), the Danish Research Agency (J.nr 271-05-0266), and the Swedish Research Council and the Swedish Cancer Society. María Apellániz-Ruiz is a predoctoral fellow of "la Caixa"/CNIO international PhD programme.

Received July 22, 2014; accepted August 5, 2014; published online July 1, 2015.

#### References

1. Abraham JE, Guo Q, Dorling L, Tyrer J, Ingle S, Hardy R, et al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. *Clin Cancer Res* 2014;20:2466-75.
2. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, et al. A genomewide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. *Clin Cancer Res* 2012;18:5099-109.
3. Leandro-García LJ, Inglada-Perez L, Pita G, Hjerpe E, Leskela S, Jara C, et al. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. *J Med Genet* 2013;50:599-605.
4. Bergmann TK, Brasch-Andersen C, Green H, Mirza M, Pedersen RS, Nielsen F, et al. Impact of CYP2C8\*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. *Pharmacogenomics J* 2011;11:113-20.
5. Coulthard MG, Morgan M, Woodruff TM, Arumugam TV, Taylor SM, Carpenter TC, et al. Eph/Ephrin signaling in injury and inflammation. *Am J Pathol* 2012;181:1493-503.

## Correction: Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel—Letter

In this letter (Clin Cancer Res 2015;21:3092–3), which was published in the July 1, 2015, issue of *Clinical Cancer Research* (1), the A/A and G/G labeling in each panel of Fig. 1 is incorrect—the labels should be reversed. A corrected version of the figure is shown below. The figure legend and main text remain unchanged. The error does not affect the conclusions set forth in the letter. The authors regret this error.




Figure 1.

### Reference

1. Apellániz-Ruiz M, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Sereno M, García-Donás J, Ávall-Lundqvist E, et al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel—letter. Clin Cancer Res 2015;21:3092–3.

Published online September 15, 2015.

doi: 10.1158/1078-0432.CCR-15-1693

©2015 American Association for Cancer Research.

# Clinical Cancer Research

## Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel—Letter

María Apellániz-Ruiz, Lara Sánchez-Barroso, Gerardo Gutiérrez-Gutiérrez, et al.

*Clin Cancer Res* 2015;21:3092-3093.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/21/13/3092>

**Cited articles** This article cites 5 articles, 3 of which you can access for free at:  
<http://clincancerres.aacrjournals.org/content/21/13/3092.full#ref-list-1>

**Citing articles** This article has been cited by 5 HighWire-hosted articles. Access the articles at:  
<http://clincancerres.aacrjournals.org/content/21/13/3092.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://clincancerres.aacrjournals.org/content/21/13/3092>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.